GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans bought 7 shares of the firm’s stock in a transaction that occurred on Tuesday, October 11th. The stock was purchased at an average price of GBX 1,728 ($21.39) per share, for a total transaction of £120.96 ($149.70).

Shares of GlaxoSmithKline plc (LON:GSK) traded down 1.11% during mid-day trading on Wednesday, hitting GBX 1700.00. The stock had a trading volume of 6,394,002 shares. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56. The firm’s market cap is GBX 82.64 billion. The stock’s 50-day moving average is GBX 1,647.81 and its 200 day moving average is GBX 1,559.14.

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (LON:GSK)

The business also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Thursday, August 11th will be issued a GBX 19 ($0.24) dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.

GSK has been the topic of a number of research analyst reports. Citigroup Inc. reiterated a “buy” rating and issued a GBX 1,800 ($22.28) target price on shares of GlaxoSmithKline plc in a research report on Friday, July 1st. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, June 21st. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a GBX 1,800 ($22.28) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, July 12th. Jefferies Group upgraded GlaxoSmithKline plc to a “buy” rating and boosted their target price for the stock from GBX 1,650 ($20.42) to GBX 2,000 ($24.75) in a research report on Thursday, July 14th. Finally, Bryan, Garnier & Co reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,685.04 ($20.85).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.